Citius Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
5493005C10W36P4KQP40 - ISIN
US17322U3068 (CTXR )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Read full profile
Fundamentals
- Net revenue
€133.00K - Gross margin
-33.9% - EBIT
-€27.06M - EBIT margin
-20,345.7% - Net income
-€36.37M - Net margin
-27,348.4%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions